Related Experiment Video

Updated: Feb 10, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

Relevant effects of beta1-adrenoceptor autoantibodies in chronic heart failure

Valerie Boivin-Jahns1, Roland Jahns2, Fritz Boege3

  • 1Institute of Pharmacology and Toxicology, University of Wuerzburg, Versbacher Str. 9, 97078 Wuerzburg Germany.

Frontiers in Bioscience (Landmark Edition)
|May 18, 2018
PubMed

Insights

Chronic heart failure (CHF) linked to autoantibodies against cardiac beta1-adrenergic receptors (beta1AR) may be treatable. Reliable detection and assessment of these autoantibodies are crucial for developing targeted therapies for CHF and other autoimmune diseases.

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • Autoantibodies against cardiac beta1-adrenergic receptors (beta1AR) are implicated in chronic heart failure (CHF).
  • The precise role of these autoantibodies in CHF pathogenesis requires further elucidation.
  • Current therapeutic strategies for CHF do not specifically address autoantibody-mediated mechanisms.

Purpose of the Study:

  • To review the current understanding of autoantibody effects on beta1AR function in CHF.
  • To discuss the potential of targeted therapies for CHF patients with specific autoantibodies.
  • To highlight the need for reliable diagnostic tools for beta1AR autoantibodies.

Main Methods:

  • Literature review of studies on autoantibodies, beta1AR, and CHF.
  • Analysis of existing data on autoantibody-mediated signaling in cardiac cells.
  • Discussion of potential therapeutic approaches like tolerance induction and antibody neutralization.

Main Results:

  • Autoantibodies against beta1AR can modulate receptor function and signal transduction.
  • These modulations are presumed to contribute to the development and progression of CHF.
  • No reliable diagnostic methods currently exist for assessing the pathogenic potential of these autoantibodies.

Conclusions:

  • Specific therapies targeting beta1AR autoantibodies could benefit selected CHF patients.
  • Accurate detection and functional assessment of beta1AR autoantibodies are essential prerequisites for such therapies.
  • This approach may also be applicable to other G-protein coupled receptor-targeting autoantibody diseases.

More Related Videos

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
993
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
947
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
391
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
356